Shahram Seyedin-Noor, JD

Shahram Seyedin-Noor is a Founder and General Partner of Civilization Ventures, a venture capital firm focused on supporting cutting-edge innovations in health care technology and biology. At Civilization, Shahram has invested in more than 50 start-ups and serves on the board of leading companies such as Rewrite Therapeutics, a gene-editing innovator acquired by Intellia Therapeutics. Prior to founding Civilization VC, he was a founding executive in several life sciences companies, including Inspirna (formerly Rgenix), a clinical-stage biotech company with first-in-class therapeutics for cancer, and NextBio, a pioneering genomics software platform acquired by Illumina. Shahram has been a pre/seed investor in category-defining start-ups such as Omada Health, Lemonaid Health (acquired by 23andMe), Counsyl (acquired by Myriad Genetics), Bina (acquired by Roche), Singular Bio (acquired by Invitae), Rocket Pharma (Nasdaq), and Avantome (acquired by Illumina). He began his career in Silicon Valley more than 20 years ago and advised some of the world’s top technology leaders while at Goldman Sachs. He earned his JD from Harvard Law School and BA in economics from Pomona College.